A cannabinoid is any chemical compound that interacts with cannabinoid receptors in your body. These compounds fall into three categories: those made by plants, those your body produces naturally, and those created in a lab. The term is most often associated with cannabis, but cannabinoids are a broader class of molecules that play a role in everything from pain perception to mood regulation.
The Three Types of Cannabinoids
Cannabinoids are classified by where they come from and how they’re structured.
Plant-derived cannabinoids (phytocannabinoids) are produced by the cannabis plant. THC and CBD are the most familiar, but roughly 120 additional minor cannabinoids have been identified in cannabis. These include CBN, CBG, and several variants like THCV and CBDV. A few non-cannabis plants also produce compounds that interact with cannabinoid receptors. Certain compounds in echinacea bind to one of these receptors, and falcarinol, a molecule found in carrots and other plants in the parsley family, shows binding activity at both major cannabinoid receptors.
Endocannabinoids are cannabinoids your body makes on its own. The two most important are anandamide and 2-AG. Anandamide got its name from the Sanskrit word for “bliss,” and it was first identified in brain tissue in 1992. These molecules are produced on demand, meaning your body synthesizes them when it needs to regulate a particular function, then breaks them down with specific enzymes once the job is done.
Synthetic cannabinoids are lab-created compounds that don’t occur naturally. They were originally developed as research tools to study how cannabinoid receptors work. Some have been developed into prescription medications, while others have appeared as unregulated drugs of abuse, often with unpredictable and dangerous effects.
How Cannabinoids Work in Your Body
All cannabinoids act through a network called the endocannabinoid system. This system has two primary receptors, called CB1 and CB2. CB1 receptors are concentrated in the brain and nervous system. CB2 receptors are found mainly in immune cells and tissues throughout the body. Both receptor types are embedded in cell membranes and belong to a large family of receptors that relay signals from outside a cell to the inside.
When a cannabinoid binds to one of these receptors, it triggers a chain of events inside the cell. Both CB1 and CB2 receptors reduce the activity of a key signaling molecule inside cells, which in turn affects how other proteins and ion channels behave. In neurons, CB1 activation changes the flow of calcium and potassium ions, making nerve cells less responsive to incoming signals. The practical result is a dampening of neurotransmitter release. This is why cannabinoids can reduce pain signaling, ease muscle spasms, or calm overactive neural circuits.
Your body’s own endocannabinoids differ in how strongly they activate these receptors. Anandamide is a partial activator at both CB1 and CB2, meaning it produces a moderate effect. 2-AG is a full activator, producing a stronger response. This distinction matters because the strength of receptor activation influences both therapeutic effects and side effects.
What THC, CBD, and Other Plant Cannabinoids Do
THC is the primary psychoactive compound in cannabis. It binds directly to CB1 receptors in the brain, producing the “high” associated with marijuana use. It also has pain-relieving, anti-nausea, and appetite-stimulating properties, which is why synthetic versions of it have been turned into prescription drugs.
CBD does not produce intoxication. It has a much weaker direct interaction with CB1 and CB2 receptors and instead appears to influence the endocannabinoid system indirectly, partly by slowing the breakdown of your body’s own endocannabinoids. CBD’s most well-established medical use is in treating severe epilepsy. In a pivotal study of 214 patients with treatment-resistant childhood epilepsy, CBD cut the median monthly seizure frequency roughly in half over 12 weeks. A later controlled trial in patients with Lennox-Gastaut syndrome found that CBD reduced the frequency of drop seizures by 37 to 42 percent compared to baseline, depending on the dose.
Beyond THC and CBD, minor cannabinoids are drawing scientific attention. Early research suggests THCV may have potential in nicotine addiction, CBDV in autism spectrum disorder symptoms, and a derivative of CBDA in anxiety and depression. These findings are preliminary, but they illustrate that different cannabinoids can have very different effects depending on their structure.
FDA-Approved Cannabinoid Medications
Four cannabinoid-based drugs currently have FDA approval. Epidiolex is the only one derived directly from the cannabis plant. It contains purified CBD and is approved for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age and older.
The other three are synthetic. Marinol and Syndros both contain a lab-made version of THC and are approved for nausea from cancer chemotherapy and appetite loss in AIDS patients. Cesamet contains nabilone, a compound structurally similar to THC, and is also approved for chemotherapy-related nausea.
Risks and Side Effects
The risks of cannabinoids depend heavily on which compound you’re talking about, how much is used, and when in life exposure occurs. CBD at therapeutic doses is generally well tolerated, with the most common issues being drowsiness and digestive discomfort. THC carries a different risk profile.
Age of first use is one of the strongest predictors of harm. Chronic cannabis use before age 17 has been linked to lasting reductions in IQ, working memory, executive functioning, decision-making, attention, and academic performance. Brain imaging studies of young users have found reduced white and gray matter integrity along with structural changes in the frontal and temporal regions of the brain. These aren’t subtle lab findings: they translate into measurable differences in everyday cognitive ability.
The psychiatric risks are also significant for early and heavy users. People who begin using cannabis before age 16 show higher rates of both positive symptoms of psychosis (like hallucinations) and negative symptoms (like emotional flatness). Early use is also associated with greater risk of depression, anxiety, and cannabis use disorder, particularly with high-THC strains. Animal research supports these findings, showing that adolescent THC exposure produces long-term changes in social behavior, motivation, and memory that persist into adulthood.
Synthetic cannabinoids sold as recreational drugs pose a separate and often more severe set of dangers. Unlike THC, which is a partial activator of cannabinoid receptors, many synthetic versions are full activators, meaning they produce a much more intense response. This makes overdose reactions, including seizures and organ damage, far more likely and unpredictable.